Literature DB >> 19010832

Microtubule active agents: beyond the taxane frontier.

Patrick G Morris1, Monica N Fornier.   

Abstract

Microtubules are essential to cell transport, signaling, and mitosis. An increasing range of anticancer drugs interferes with the normal formation and function of microtubules. Vinca alkaloids act as microtubule destabilizers and the taxanes act as microtubule stabilizers. Taxanes are widely used cytotoxic agents that are active in a range of solid tumor malignancies and are routinely used in a variety of settings. Significant limitations with the taxanes exist, including acquired and intrinsic tumor resistance through the expression of multidrug resistance proteins such as P-glycoprotein, risk of hypersensitivity reactions, dose-limiting hematopoietic toxicity, and cumulative neurotoxicity. Hence, there is a need to develop novel agents that act on the microtubules. Epothilones are macrolide antibiotics that bind near the taxane-binding site on microtubules and have been extensively studied in recent and ongoing clinical trials. A variety of other agents that act on the microtubules at different sites with a variety of structures are at varying stages of development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010832     DOI: 10.1158/1078-0432.CCR-08-0169

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

Review 1.  Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Authors:  Claudia M Hattinger; Serena Vella; Elisa Tavanti; Marilù Fanelli; Piero Picci; Massimo Serra
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

2.  In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.

Authors:  V G Minero; D De Stefanis; P Costelli; F M Baccino; G Bonelli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Taccalonolides: Novel microtubule stabilizers with clinical potential.

Authors:  April L Risinger; Susan L Mooberry
Journal:  Cancer Lett       Date:  2009-10-31       Impact factor: 8.679

4.  Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.

Authors:  Maged Henary; Lakshminarayana Narayana; Shazia Ahad; Sushma R Gundala; Rao Mukkavilli; Vibhuti Sharma; Eric A Owens; Yogesh Yadav; Mulpuri Nagaraju; Donald Hamelberg; Vibha Tandon; Dulal Panda; Ritu Aneja
Journal:  Biochem Pharmacol       Date:  2014-08-11       Impact factor: 5.858

5.  First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.

Authors:  Patricia M LoRusso; Priscila H Goncalves; Lindsay Casetta; Judith A Carter; Kevin Litwiler; Dale Roseberry; Selena Rush; Jennifer Schreiber; Heidi M Simmons; Mieke Ptaszynski; Edward A Sausville
Journal:  Invest New Drugs       Date:  2015-02-17       Impact factor: 3.850

6.  Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Authors:  Kinsie E Arnst; Yuxi Wang; Zi-Ning Lei; Dong-Jin Hwang; Gyanendra Kumar; Dejian Ma; Deanna N Parke; Qiang Chen; Jinliang Yang; Stephen W White; Tiffany N Seagroves; Zhe-Sheng Chen; Duane D Miller; Wei Li
Journal:  Mol Pharmacol       Date:  2019-05-01       Impact factor: 4.436

7.  Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.

Authors:  Elisa Barile; Si Wang; Swadesh K Das; Roberta Noberini; Russell Dahl; John L Stebbins; Elena B Pasquale; Paul B Fisher; Maurizio Pellecchia
Journal:  ChemMedChem       Date:  2014-03-26       Impact factor: 3.466

Review 8.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

9.  Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.

Authors:  Murali M Yallapu; Diane M Maher; Vasudha Sundram; Maria C Bell; Meena Jaggi; Subhash C Chauhan
Journal:  J Ovarian Res       Date:  2010-04-29       Impact factor: 4.234

10.  Castrate-resistant prostate cancer: postdocetaxel management.

Authors:  Song Zhao; Evan Y Yu
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.